This content is machine translated Biologics for AD Interleukin-13 as a target – new long-term data available Now that the range of systemic therapeutics for atopic dermatitis has been expanded and the two monoclonal antibodies dupilumab and tralokinumab as well as three Janus kinase inhibitors have been…
View Post 4 min This content is machine translated Dupilumab for COPD and asthma Exacerbations reduced and lung function improved The monoclonal antibody dupilumab blocks the common receptor component for interleukin (IL)-4 and IL-13, the central drivers of type 2 inflammation. It has been approved in Switzerland since 2019, and…
View Post 16 min This content is machine translated Moderate to severe atopic dermatitis Changing therapeutic landscape – broad arsenal of treatment options New therapies in the form of specific antibodies and “small molecules” have ushered in a new era. Biologics intervene in the inflammatory process of atopic dermatitis by targeting individual cytokines.… CME-Test
View Post 4 min This content is machine translated Moderate to severe atopic dermatitis IL-13 blockade – an innovative treatment approach with great potential The spectrum of systemic treatment options for atopic dermatitis is currently in flux. In recent years, the interleukin (IL)-13 pathway has been shown to play an essential role in the…
